rs773891669
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_024642.5(GALNT12):c.925A>G(p.Thr309Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000254 in 1,611,948 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T309I) has been classified as Uncertain significance.
Frequency
Consequence
NM_024642.5 missense
Scores
Clinical Significance
Conservation
Publications
- colorectal cancer, susceptibility to, 1Inheritance: AD Classification: LIMITED Submitted by: ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GALNT12 | ENST00000375011.4 | c.925A>G | p.Thr309Ala | missense_variant | Exon 5 of 10 | 1 | NM_024642.5 | ENSP00000364150.3 | ||
| GALNT12 | ENST00000610463.1 | n.*356A>G | non_coding_transcript_exon_variant | Exon 4 of 4 | 4 | ENSP00000477657.1 | ||||
| GALNT12 | ENST00000610463.1 | n.*356A>G | 3_prime_UTR_variant | Exon 4 of 4 | 4 | ENSP00000477657.1 |
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152240Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000318 AC: 8AN: 251478 AF XY: 0.0000294 show subpopulations
GnomAD4 exome AF: 0.0000247 AC: 36AN: 1459708Hom.: 0 Cov.: 30 AF XY: 0.0000193 AC XY: 14AN XY: 726322 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152240Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74368 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2
This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 309 of the GALNT12 protein (p.Thr309Ala). This variant is present in population databases (rs773891669, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with GALNT12-related conditions. ClinVar contains an entry for this variant (Variation ID: 410577). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GALNT12 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
The variant has not been reported in the published literature. The frequency of this variant in the general population, 0.000085 (11/129194 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Colorectal cancer, susceptibility to, 1 Uncertain:2
- -
- -
not specified Uncertain:1
The p.T309A variant (also known as c.925A>G), located in coding exon 5 of the GALNT12 gene, results from an A to G substitution at nucleotide position 925. The threonine at codon 309 is replaced by alanine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Hereditary cancer-predisposing syndrome Uncertain:1
The missense variant NM_024642.5(GALNT12):c.925A>G (p.Thr309Ala) has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. There is a small physicochemical difference between threonine and alanine, which is not likely to impact secondary protein structure as these residues share similar properties. The p.Thr309Ala missense variant is predicted to be damaging by both SIFT and PolyPhen2. The threonine residue at codon 309 of GALNT12 is conserved in all mammalian species. The nucleotide c.925 in GALNT12 is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at